Researchers at the University of British Columbia have found a new way to block infection from the hepatitis C virus (HCV) in the liver that could lead to new therapies for those affected by this and other infectious diseases.
More than 170 million people worldwide suffer from hepatitis C, the disease caused by chronic HCV infection. The disease affects the liver and is one of the leading causes of liver cancer and liver transplant around the world. HCV is spread by blood-to-blood contact and there is no vaccine to prevent it. Current treatments for the disease are only moderately effective and can cause serious side effects.
"As HCV infects a person, it needs fat droplets in the liver to form new virus particles," says Franηois Jean, Associate Professor in the Department of Microbiology and Immunology and Scientific Director of the Facility for Infectious Disease and Epidemic Research (FINDER) at UBC. "In the process, it causes fat to accumulate in the liver and ultimately leads to chronic dysfunction of the organ."
"HCV is constantly mutating, which makes it difficult to develop antiviral therapies that target the virus itself," says Jean. "So we decided to take a new approach."
Jean and his team developed an inhibitor that decreases the size of host fat droplets in liver cells and stops HCV from "taking residence," multiplying and infecting other cells.
"Our approach would essentially block the lifecycle of the virus so that it cannot spread and cause further damage to the liver," says Jean. The team's method is detailed in the journal PLoS Pathogens.
According to Jean, HCV is one of a number of viruses that require fat to replicate in the human body. This new approach to curbing the replication of HCV could translate into similar therapies for other related re-emerging viruses that can cause serious and life threatening infections in humans, such as dengue virus. Dengue is endemic in more than 100 countries, with approximately 2.5 billion people at risk of infection globally. In some countries, Dengue has become the leading cause of child mortality.
The research was supported by the Canadian Institutes of Health Research (CIHR) through grants and scholarships and by the Michael Smith Foundation for Health Research (MSFHR) through its Junior Trainee Award.
- Andrea D. Olmstead, Wolfgang Knecht, Ina Lazarov, Surjit B. Dixit, Franηois Jean. Human Subtilase SKI-1/S1P Is a Master Regulator of the HCV Lifecycle and a Potential Host Cell Target for Developing Indirect-Acting Antiviral Agents. PLoS Pathogens, 2012; 8 (1): e1002468 DOI: 10.1371/journal.ppat.1002468
Cite This Page: